LLY: Financial results

Item 2.02. Results of Operations and Financial Condition. The information in this Item 2.02, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”), or otherwise subject to the liabilities of that Section and shall not be incorporated by reference into any registration statement or other document filed pursuant to the Securities Act of 1933 or the Exchange Act, except as otherwise expressly stated in such filing. Attached hereto as Exhibit 99.1 and incorporated by reference into this Item 2.02 is a copy of the press release, dated October 29, 2026, announcing the financial results of Eli Lilly and Company for the quarter ended September 30, 2026. Item 9.01. Financial Statements and Exhibits. Exhibit No. Description 99.1 Press Release of Eli Lilly and Company, dated October 29 , 2026. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. ELI LILLY AND COMPANY (Registrant) By: /s/ Donald A. Zakrowski Name: Donald A. Zakrowski Title: Senior Vice President, Finance, and Chief Accounting Officer Date: October 29, 2026